% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • njcheesehead05 njcheesehead05 Dec 10, 2013 4:41 PM Flag

    CDX-301 Licensed from Amgen

    According to the November 3, 2011 10-Q, we licensed 301 from Amgen. Does it stand to reason that the Mice used in this study are also the Amgen immune system mice?

    Either way it is good to see positive results from $14.5M investments.

    If anyone has more info I would appreciate it. Also, does anyone know if the license agreement with Amgen is a part of future proceeds of 301 or a agreement to use Amgen tech to study new areas?

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Cheese,
      I never expected cdx-301 to be tested as a treatment for Lymphoma. And the great thing is Celldex is not paying for the study. cdx-301 could be the icing on the cake for Celldex.

      In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
      This study is currently recruiting participants.
      Verified December 2013 by Mount Sinai School of Medicine
      Joshua Brody
      Information provided by (Responsible Party):
      Joshua Brody, Mount Sinai School of Medicine
      Low-Grade B-cell Lymphoma
      Drug: rhuFlt3L/CDX-301
      Drug: Poly-ICLC

      Sentiment: Strong Buy

      • 2 Replies to weightbayou
      • Thanks Weight, I saw the post earlier. I did not make the connection that they moved a study to Lymphoma. I saw the long quote and thought it was a re-post of old news about the mice.

        Take care.

      • The Lymphoma Immunotherapy Program at the Mount Sinai School of Medicine and the Brody Lab focus on basic and applied tumor immunology (particularly in lymphoma, melanoma, and ovarian adenocarcinoma). Other areas of interest include: bioinformatic-based collaborations tracking T-cell responses using high-throughput sequencing of the entire TCRbV repertoire and studies of small-molecule inhibitors of lymphocyte signal transduction, e.g. PI3K, mTOR, btk. Our lab has the rare opportunity to both perform correlative studies on primary patient tumor samples from early phase clinical trials and to continually develop advancements in those trials based on what is learned. The core mission is the translation of basic science in tumor immunology into novel clinical trials and development of correlative science associated with those trials to gain a greater understanding of mechanistic-clinical correlates.

        Dr. Brody is a top man in cancer.

        Awards2011 -
        SCL Award for top abstract submitted to 2011 International Conference on Malignant Lymphoma
        Swiss Cancer League

        2011 -
        Society for Immunotherapy of Cancer Presidential Award (SITC 26th Annual Meeting)

        2011 -
        ASCO Merit Award for top 100 abstracts submitted to 2011 Annual Meeting
        American Society of Clinical Oncology

        2009 - 2014
        Howard Temin Pathway to Independence Award in Cancer Research (K99/R00) – [1 K99 CA140728-01] ”Immunotransplant to Treat Lymphoma” – 09/09 – 08/14

        2009 -
        ‘Outstanding Recent Graduate’
        SUNY Stony Brook School of Medicine

        2008 -
        William Guy Forbeck Scholar Award – invited to present at 2008 Forum
        William Guy Forbeck Research Foundation

        2008 -
        MCLC featured researcher
        Mantle Cell Lymphoma Consortium

        2008 -
        ASCO Bradley Stuart Beller Foundation Fellowship Merit Award for best abstract submitted to 2008 Annual Meeting
        American Society of Clinical Oncology

    • Has anyone read any info on this one?

    • Maybe long could chime in

3.49+0.02(+0.58%)Aug 26 4:00 PMEDT